This company listing is no longer active
G5B Stock Overview
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD).
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Global Blood Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$68.40 |
| 52 Week High | US$70.48 |
| 52 Week Low | US$20.83 |
| Beta | 0.46 |
| 1 Month Change | 2.18% |
| 3 Month Change | 110.88% |
| 1 Year Change | 212.76% |
| 3 Year Change | 62.86% |
| 5 Year Change | 144.90% |
| Change since IPO | 48.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| G5B | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.5% | -1.0% | -1.2% |
| 1Y | 212.8% | -15.4% | 1.2% |
Return vs Industry: G5B exceeded the German Biotechs industry which returned -9.2% over the past year.
Return vs Market: G5B exceeded the German Market which returned -24.5% over the past year.
Price Volatility
| G5B volatility | |
|---|---|
| G5B Average Weekly Movement | 17.1% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: G5B's share price has been volatile over the past 3 months.
Volatility Over Time: G5B's weekly volatility has increased from 12% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 457 | Ted Love | www.gbt.com |
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
Global Blood Therapeutics, Inc. Fundamentals Summary
| G5B fundamental statistics | |
|---|---|
| Market cap | €4.69b |
| Earnings (TTM) | -€327.07m |
| Revenue (TTM) | €238.22m |
19.7x
P/S Ratio-14.3x
P/E RatioIs G5B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G5B income statement (TTM) | |
|---|---|
| Revenue | US$234.86m |
| Cost of Revenue | US$4.45m |
| Gross Profit | US$230.41m |
| Other Expenses | US$552.87m |
| Earnings | -US$322.46m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.78 |
| Gross Margin | 98.10% |
| Net Profit Margin | -137.30% |
| Debt/Equity Ratio | 491.7% |
How did G5B perform over the long term?
See historical performance and comparison